1. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. (1997) Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke.
Neuropathol Appl Neurobiol, 23 (5): 406-15.
[PMID:9364466]
2. Appleby TC, Greenstein AE, Hung M, Liclican A, Velasquez M, Villaseñor AG, Wang R, Wong MH, Liu X, Papalia GA et al.. (2017) Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9.
J Biol Chem, 292 (16): 6810-6820.
[PMID:28235803]
3. AstraZeneca. AZD1236.
Accessed on 31/10/2014. Modified on 31/10/2014.
Open Innovation, http://openinnovation.astrazeneca.com/what-we-offer/compound/azd1236/
4. Benesová Y, Vasku A, Novotná H, Litzman J, Stourac P, Beránek M, Kadanka Z, Bednarík J. (2009) Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
Mult Scler, 15 (3): 316-22.
[PMID:19153173]
5. Brown S, Bernardo MM, Li Z-H, Kotra LP, Tanaka Y, Fridman R, Mobashery S. (2000) Potent and Selective Mechanism-Based Inhibition of Gelatinases.
J Am Chem Soc, 122: 6799-6800.
6. Cataldo D, Munaut C, Noël A, Frankenne F, Bartsch P, Foidart JM, Louis R. (2000) MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease.
Int Arch Allergy Immunol, 123 (3): 259-67.
[PMID:11112863]
7. Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX. (2013) Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.
J Med Chem, 56 (11): 4357-73.
[PMID:23631440]
8. Kirkegaard T, Hansen A, Bruun E, Brynskov J. (2004) Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease.
Gut, 53 (5): 701-9.
[PMID:15082589]
9. Lakatos G, Sipos F, Miheller P, Hritz I, Varga MZ, Juhász M, Molnár B, Tulassay Z, Herszényi L. (2012) The behavior of matrix metalloproteinase-9 in lymphocytic colitis, collagenous colitis and ulcerative colitis.
Pathol Oncol Res, 18 (1): 85-91.
[PMID:21678108]
10. Ma D, Wu W, Yang G, Li J, Li J, Ye Q. (2004) Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
Bioorg Med Chem Lett, 14 (1): 47-50.
[PMID:14684295]
11. Marshall DC, Lyman SK, McCauley S, Kovalenko M, Spangler R, Liu C, Lee M, O'Sullivan C, Barry-Hamilton V, Ghermazien H et al.. (2015) Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer.
PLoS ONE, 10 (5): e0127063.
[PMID:25961845]
12. Moriyama H, Tsukida T, Inoue Y, Yokota K, Yoshino K, Kondo H, Miura N, Nishimura S. (2004) Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.
J Med Chem, 47 (8): 1930-8.
[PMID:15055993]
13. MRC. AZD6605 Matrix metallopeptidase 13 (MMP13) inhibitor.
Accessed on 28/10/2014. Modified on 28/10/2014.
MRC/AstraZeneca: Mechanisms of Disease Call, http://webarchive.nationalarchives.gov.uk/20120104105854/http://www.mrc.ac.uk/consumption/groups/public/documents/content/mrc008371.pdf
14. Nguyen TT, Ding D, Wolter WR, Pérez RL, Champion MM, Mahasenan KV, Hesek D, Lee M, Schroeder VA, Jones JI et al.. (2018) Validation of Matrix Metalloproteinase-9 (MMP-9) as a Novel Target for Treatment of Diabetic Foot Ulcers in Humans and Discovery of a Potent and Selective Small-Molecule MMP-9 Inhibitor That Accelerates Healing.
J Med Chem, 61 (19): 8825-8837.
[PMID:30212201]
15. Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E et al.. (2011) Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.
Eur J Med Chem, 46 (7): 2617-29.
[PMID:21514700]
16. Rasmussen HS, McCann PP. (1997) Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat.
Pharmacol Ther, 75 (1): 69-75.
[PMID:9364582]
17. Takeuchi T, Hayashi M, Tamita T, Nomura Y, Kojima N, Mitani A, Takeda T, Hitaka K, Kato Y, Kamitani M et al.. (2022) Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
J Med Chem, 65 (12): 8493-8510.
[PMID:35687819]
18. Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL et al.. (2001) Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.
J Med Chem, 44 (16): 2636-60.
[PMID:11472217]
19. Yong VW, Zabad RK, Agrawal S, Goncalves Dasilva A, Metz LM. (2007) Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators.
J Neurol Sci, 259: 79-84.
[PMID:17382965]